April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.
E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.
On April 29, 2016, Health Canada licensed the sale and use of a new fixed-dose combination of two anti-HIV drugs sold under the brand name Descovy.
Descovy (emtricitabine/tenofovir alafenamide) is the third approved HIV drug to include tenofovir alafenamide (TAF), which has been shown to have better bone and kidney safety than its predecessor tenofovir disoproxil fumarate (TDF, Viread).
The FDA has approved Descovy, Gilead Sciences' latest combination pill containing emtricitabine and an updated version of tenofovir.